MAGIC-AF Trial design: Patients with persistent atrial fibrillation (AF) and remaining in AF after pulmonary vein isolation alone were randomized to either.

Slides:

Advertisements

Similar presentations

Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)

Advertisements

Optimal Method and Outcomes of Catheter Ablation of Persistent AF: The STAR AF 2 Trial Atul Verma, Jiang Chen-yang, Tim Betts, John Radcliffe, Jian Chen,

Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.

John R Onufer MD FHRS.  Paroxysmal(that which terminates spontaneously) Persistent Sustained > 7 days, or lasting < 7 days but requires pharmacologic.

Late outcomes of the Cox-Maze IV procedure for atrial fibrillation Matthew C. Henn MD, Timothy S. Lancaster MD, Jacob R. Miller MD, Laurie A. Sinn RN,

Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial by Atul Verma, Roberto Mantovan,

AF: Catheter Ablation Isolation of the 4 pulmonary veins Linear lesions to create additional lines of block 1.

Redo afib ablation John R Onufer MD FHRS

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Asklepios Klink St. Georg, Hamburg

SWEDMAF Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Carina Blomstrom-Lundqvist SWEDMAF Trial.

A-4 Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Pierre Jais Atrial Fibrillation Ablation vs. Antiarrhythmic Drugs Trial.

One year follow-up after cryoballoon isolation of the pulmonary veins in patients with paroxysmal atrial fibrillation by Yves Van Belle, Petter Janse,

Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Randomized Trial to Assess Catheter Ablation Versus.

Catheter Ablation of Atrial Fibrillation by Roderick Tung, Eric Buch, and Kalyanam Shivkumar Circulation Volume 126(2): July 10, 2012 Copyright.

Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation Jens Cosedis Nielsen, M.D., D.M.Sc., Arne Johannessen, M.D., D.M.Sc., Pekka.

Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: A randomized trial of the ostial.

IRIS Trial design: Patients without diabetes with a history of stroke or TIA within 6 months, with objective evidence of insulin resistance (HOMA-IR value.

Rationale and design of the FreezeAF trial: A randomized controlled noninferiority trial comparing isolation of the pulmonary veins with the cryoballoon.

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.

Circ Arrhythm Electrophysiol

Circ Arrhythm Electrophysiol

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

Where does atrial fibrillation surgery fail

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

AARDVARK Trial design: Patients with small abdominal aortic aneuryms (AAAs) were randomized in a 1:1:1 fashion to either perindopril 10 mg once daily,

LEVO-CTS Trial design: Patients undergoing cardiac surgery with the use of cardiopulmonary bypass were randomized to infusion of levosimendan 0.2 µg/kg/min.

(p for noninferiority = )

Angiography-guided PCI

BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.

(pnoninferiority < )

Initial Experience of Sequential Surgical Epicardial-Catheter Endocardial Ablation for Persistent and Long-Standing Persistent Atrial Fibrillation With.

MARFAN SARTAN Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those

Losartan vs. Atenolol in Marfan Syndrome

ALPS Trial design: Patients with adult nontraumatic out-of-hospital cardiac arrest (OOHCA) and persistent or recurrent VT/VF after ≥1 shock were randomized.

FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.

Catheter Ablation for the Cure of Atrial Fibrillation Study

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

CANOA Trial design: Patients undergoing percutaneous closure of an ASD with the Amplatzer Septal Occluder were randomized to aspirin 80 mg plus clopidogrel.

FAMOUS-NSTEMI Trial design: Participants with NSTEMI were randomized to an FFR-guided strategy (n = 176) vs. a coronary angiography-guided strategy (n.

ATMOSPHERE Trial design: Patients with symptomatic heart failure were randomized in a 1:1:1 fashion to either aliskiren 300 mg once daily, enalapril 5.

Volume 14, Issue 5, Pages (May 2017)

PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.

Jose C. Pachon M. et al. JACEP 2015;1:

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

ΝΟΣΟΣ ΤΑΧΥΒΡΑΔΥΚΑΡΔΙΑΣ: ΕΜΦΥΤΕΥΣΗ ΒΗΜΑΤΟΔΟΤΗ Η ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ ; ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ ΕΠ.Α ΚΑΡΔΙΟΛΟΓΟΣ ΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ.

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

AFACT Trial design: Patients with long-standing atrial fibrillation were randomized to ganglion plexus ablation (n = 117) vs. control (n = 123) on top.

Volume 12, Issue 9, Pages (September 2015)

Ranolazine in Microvascular Dysfunction

David J Wilber MD Loyola University Chicago

OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,

Risk Factor Modification

Amir Jadidi et al. JACEP 2018;4:

IMPRESSION Trial design: Patients presenting with acute MI and undergoing an invasive approach, along with ticagrelor loading dose, were randomized to.

Stavros Stavrakis et al. JACEP 2015;1:1-13

Pouria Alipour et al. JACEP 2017;j.jacep

The procedural journey for our cohort of patients with persistent atrial fibrillation. The procedural journey for our cohort of patients with persistent.

POPE-2 Trial design: Patients with moderate to large pericardial effusion after cardiac surgery were randomized to colchicine 2 mg loading dose, then 1.

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

Metoprolol for AR Trial design: Patients with chronic asymptomatic severe aortic regurgitation (AR) were randomized to metoprolol CR/XL 200 mg or matching.

Anna Björkenheim et al. JACEP 2017;j.jacep

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Volume 14, Issue 9, Pages (September 2017)

TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)

International Journal of Cardiology

STOP-CHAGAS Trial design: Asymptomatic patients with serological evidence of T. cruzi were randomized to posaconazole 400 mg BID, benznidazole 200 mg BID,

Jose C. Pachon M. et al. JACEP 2015;1:

(p for noninferiority = 0.01)

Presentation transcript:

MAGIC-AF Trial design: Patients with persistent atrial fibrillation (AF) and remaining in AF after pulmonary vein isolation alone were randomized to either intravenous ibutilide 0.25 mg or placebo. They were followed for 1 year. Results (p = 0.38) Primary efficacy endpoint, freedom from recurrent atrial arrhythmia >30 seconds after one ablation procedure without use of AADs (3-month post-ablation blanking period), for ibutilide vs. placebo: 56% vs. 49%, p = 0.38 Endpoint with or without AAD use: 62% vs. 51%, p = 0.14 AF termination with CFAE ablation: 71% vs. 56%, p = 0.03 % Conclusions Ibutilide-guided CFAE ablation was not efficacious in improving procedural characteristics or freedom from atrial arrhythmias at 12 months in patients with persistent AF However, ibutilide administration does reduce left atrial surface area with CFAE and is associated with greater AF termination rates during catheter ablation Primary endpoint Ibutilide (n = 105) Placebo (n = 95) Singh SM, et al. Eur Heart J 2016;Feb 4:[Epub]